tranexamic acid has been researched along with Deep Vein Thrombosis in 115 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of this study was to assess the safety of tranexamic acid (TXA) utilization with respect to the incidence of deep venous thrombosis (DVT) in hemophiliacs undergoing total knee arthroplasty (TKA)." | 9.69 | Tranexamic acid is safe with respect to the risk of deep venous thrombosis in patients with hemophilic arthritis undergoing total knee arthroplasty without chemoprophylaxis: A prospective study. ( Guo, JJ; Yu, Z; Zhang, Q; Zhao, L, 2023) |
| "Background and Objectives: Previous studies regarding tranexamic acid (TXA) in total knee arthroplasty (TKA) investigated only symptomatic deep vein thrombosis (DVT), or did not include high risk patients." | 8.12 | Topical Tranexamic Acid Can Be Used Safely Even in High Risk Patients: Deep Vein Thrombosis Examination Using Routine Ultrasonography of 510 Patients. ( An, BK; Joo, YB; Kim, YM; Kwon, ST; Lee, CW; Song, JH, 2022) |
| "Tranexamic acid (TXA) is used as a hemostatic adjunct for hemorrhage control in the injured patient and reduces early preventable death." | 7.91 | Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. ( Brown, JB; Kutcher, ME; Myers, SP; Neal, MD; Peitzman, AB; Rosengart, MR; Sperry, JL, 2019) |
| "The major concern with the use of tranexamic acid is that it may promote a hypercoagulable state and increase the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly when chemical thromboprophylaxis is not used." | 7.85 | Chemical Thromboprophylaxis Is Not Necessary to Reduce Risk of Thromboembolism With Tranexamic Acid After Total Hip Arthroplasty. ( Kim, JS; Kim, YH; Park, JW, 2017) |
| " The purpose of this study was to assess the safety of tranexamic acid (TXA) utilization with respect to the incidence of deep venous thrombosis (DVT) in hemophiliacs undergoing total knee arthroplasty (TKA)." | 5.69 | Tranexamic acid is safe with respect to the risk of deep venous thrombosis in patients with hemophilic arthritis undergoing total knee arthroplasty without chemoprophylaxis: A prospective study. ( Guo, JJ; Yu, Z; Zhang, Q; Zhao, L, 2023) |
| "VTE recurrence was not significantly greater in those who received TXA (2." | 5.46 | Tranexamic Acid Was Safe in Arthroplasty Patients With a History of Venous Thromboembolism: A Matched Outcome Study. ( Abdel, MP; Amundson, AW; Larson, DR; Pagnano, MW; Sabbag, OD, 2017) |
| "Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA." | 5.43 | Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016) |
| "Tranexamic acid (TXA) has been used to reduce blood loss during total hip arthroplasty (THA), but its use could increase the risk of venous thromboembolic disease (VTE)." | 5.42 | Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis? ( Hamada, M; Nishihara, S, 2015) |
| "We examined the blood conserving effect of tranexamic acid in total hip arthroplasty using the direct anterior approach with enoxaparin as deep vein thrombosis (DVT) chemoprophylaxis, and whether this translates to an effect on functional outcomes in the perioperative period." | 5.30 | OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial. ( Duggan, J; Duncan, S; Fraval, A; Murray, T; Tirosh, O; Tran, P, 2019) |
| "The objective of this study was to ascertain whether combined intravenous (IV) and intra-articular (IA) administration of tranexamic acid (TXA) is beneficial for reducing blood loss and the prevalence of deep venous thrombosis (DVT) in primary simultaneous bilateral total knee arthroplasty compared with IV only administration of TXA." | 5.27 | Comparative Efficacy of Intravenous With Intra-articular Versus Intravenous Only Administration of Tranexamic Acid to Reduce Blood Loss in Knee Arthroplasty. ( Kim, JS; Kim, YH; Pandey, K; Park, JW, 2018) |
| "Systemic administration of TXA can effectively reduce the postoperative blood loss which results in lower rate of transfusion requirement and wound hematoma in minimally invasive TKA patients when rivaroxaban is used for thromboprophylaxis." | 5.24 | The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial. ( Chen, B; Huang, CC; Kuo, FC; Lin, PC; Wang, JW; Yen, SH, 2017) |
| "This systematic review was undertaken to answer three specific questions relating to the clinical values of tranexamic acid (TNA) in total knee arthroplasty (TKA): (1) Whether there are differences in blood-saving effects between the systemic and topical administrations; (2) Whether blood-saving effects of TNA differ by doses and timings of administration; and (3) Whether the use of TNA is safe at all reported doses, timings, and routes of administration with respect to the incidences of symptomatic deep-vein thrombosis (DVT) and pulmonary embolism (PE)." | 4.90 | Practical issues for the use of tranexamic acid in total knee arthroplasty: a systematic review. ( Chang, CB; Kim, TK; Koh, IJ, 2014) |
| "Background and Objectives: Previous studies regarding tranexamic acid (TXA) in total knee arthroplasty (TKA) investigated only symptomatic deep vein thrombosis (DVT), or did not include high risk patients." | 4.12 | Topical Tranexamic Acid Can Be Used Safely Even in High Risk Patients: Deep Vein Thrombosis Examination Using Routine Ultrasonography of 510 Patients. ( An, BK; Joo, YB; Kim, YM; Kwon, ST; Lee, CW; Song, JH, 2022) |
| "Tranexamic acid (TXA) is used as a hemostatic adjunct for hemorrhage control in the injured patient and reduces early preventable death." | 3.91 | Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. ( Brown, JB; Kutcher, ME; Myers, SP; Neal, MD; Peitzman, AB; Rosengart, MR; Sperry, JL, 2019) |
| "To ascertain whether tranexamic acid reduces the blood loss and transfusion rate and volumes; increase the prevalence of deep vein thrombosis (DVT); and investigate factors associated with DVT in patients undergoing primary bilateral total knee arthroplasties (TKAs) without use of chemical thromboprophylaxis." | 3.88 | Does tranexamic acid increase the risk of thromboembolism after bilateral simultaneous total knee arthroplasties in Asian Population? ( Kim, JS; Kim, YH; Park, JW; Seo, DH, 2018) |
| "The major concern with the use of tranexamic acid is that it may promote a hypercoagulable state and increase the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly when chemical thromboprophylaxis is not used." | 3.85 | Chemical Thromboprophylaxis Is Not Necessary to Reduce Risk of Thromboembolism With Tranexamic Acid After Total Hip Arthroplasty. ( Kim, JS; Kim, YH; Park, JW, 2017) |
| "Tranexamic acid (TXA) is a standard component of Tactical Combat Casualty Care." | 3.01 | A Systematic Review of Tranexamic Acid-Associated Venous Thromboembolic Events in Combat Casualties and Considerations for Prolonged Field Care. ( Ho, JW; Keeney-Bonthrone, TP; Lozano, R; Ruf, AC; Russo, RM; Strayve, D; Zakaluzny, SA, 2023) |
| "Anemia is one of the most common complications after hip fracture surgery." | 3.01 | Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis. ( Augustinus, S; Gardenbroek, TJ; Goslings, JC; Mulders, MAM, 2023) |
| " The ongoing trials create six new comparisons: tranexamic acid (tablet + injection) versus placebo; intravenous tranexamic acid versus oral tranexamic acid; topical tranexamic acid versus oral tranexamic acid; different intravenous tranexamic acid dosing regimes; topical tranexamic acid versus topical fibrin glue; and fibrinogen (injection) versus placebo." | 3.01 | Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint replacement for hip, pelvic and long bone fractures. ( Brunskill, SJ; Champaneria, R; Dorée, C; Estcourt, LJ; Geneen, LJ; Gibbs, VN; Novak, A; Palmer, AJ; Raval, P, 2023) |
| "Tranexamic acid (TXA) has been reported to reduce perioperative blood loss in hip or knee arthroplasty." | 3.01 | Efficacy and safety of single- and double-dose intravenous tranexamic acid in hip and knee arthroplasty: a systematic review and meta-analysis. ( Cheng, QH; Guo, HZ; Yang, X; Yang, YZ; Zhang, AR; Zhang, ZZ, 2023) |
| "Elderly patients with intertrochanteric fractures exhibit post-traumatic hidden blood loss (HBL)." | 3.01 | Early intravenous tranexamic acid intervention reduces post-traumatic hidden blood loss in elderly patients with intertrochanteric fracture: a randomized controlled trial. ( Chen, X; He, T; Li, M; Liu, L; Liu, X; Long, X; Ma, H; Wang, H; Wang, W; Xu, Z, 2021) |
| "The primary outcome was postpartum hemorrhage, defined as a calculated estimated blood loss greater than 1000 ml or receipt of a red-cell transfusion within 2 days after delivery." | 3.01 | Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery. ( Azria, E; Benard, A; Bohec, C; Bretelle, F; Chauleur, C; Daniel, V; Darsonval, A; de Marcillac, F; Deneux-Tharaux, C; Desbrière, R; Fuchs, F; Gallot, D; Gauchotte, E; Georget, A; Haddad, B; Kayem, G; Korb, D; Le Lous, M; Le Ray, C; Legendre, G; Letouzey, V; Madar, H; Mattuizzi, A; Mottet, N; Parant, O; Perrotin, F; Regueme, S; Roussillon, C; Rozenberg, P; Salomon, LJ; Sananès, N; Sénat, MV; Sentilhes, L; Vardon, D; Verspyck, E; Winer, N, 2021) |
| "Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98)." | 2.94 | Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. ( , 2020) |
| "Deep venous thrombosis (DVT) and pulmonary embolism (PE) events were monitored and recorded." | 2.94 | Combined use of intravenous and topical tranexamic acid efficiently reduces blood loss in patients aged over 60 operated with a 2-level lumbar fusion. ( Bai, T; Huang, Y; Li, J; Liu, Y; Wang, L, 2020) |
| "Tranexamic acid (TXA) has long been used to reduce blood loss associated with total knee arthroplasty (TKA)." | 2.90 | Comparison of oral vs. combined topical/intravenous/oral tranexamic acid in the prevention of blood loss in total knee arthroplasty: A randomised clinical trial. ( Bernaitis, N; Dare, W; King, L; Randle, R, 2019) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug." | 2.90 | Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels. ( Baaklini, LR; Cross, JR; Fields, KG; Jules-Elysee, KM; Mayman, DJ; McLawhorn, AS; Pickard, AJ; Qin, W; Sculco, TP; Su, EP; Tseng, A, 2019) |
| "No episodes of deep venous thrombosis or pulmonary embolism occurred in all cases." | 2.87 | Multiple-Dose Intravenous Tranexamic Acid Further Reduces Hidden Blood Loss After Total Hip Arthroplasty: A Randomized Controlled Trial. ( Chen, G; Huang, Q; Huang, Z; Lei, Y; Pei, F; Xie, J, 2018) |
| "Only one patient in IV group exhibited deep venous thrombosis." | 2.87 | Tranexamic acid in primary total knee arthroplasty without tourniquet: a randomized, controlled trial of oral versus intravenous versus topical administration. ( Cao, C; Li, DH; Li, LL; Meng, WK; Pei, FX; Wang, D; Wang, HY; Zeng, WN; Zhou, ZK, 2018) |
| "No deep venous thrombosis or other severe complications had occurred." | 2.84 | Intra-articular Application is More Effective Than Intravenous Application of Tranexamic Acid in Total Knee Arthroplasty: A Prospective Randomized Controlled Trial. ( Wang, J; Wang, Q; Zhang, X, 2017) |
| "The total blood loss and postoperative blood loss were significantly lower in groups B and C without any difference between them." | 2.84 | Efficacy of a Single Dose and an Additional Dose of Tranexamic Acid in Reduction of Blood Loss in Total Knee Arthroplasty. ( Cai, M; Ge, W; Li, S; Sun, Q; Wu, J; Yu, X, 2017) |
| "The optimal dosage and timing of tranexamic acid (TXA) in total knee arthroplasty (TKA) are undetermined." | 2.82 | Multiple Boluses of Intravenous Tranexamic Acid to Reduce Hidden Blood Loss After Primary Total Knee Arthroplasty Without Tourniquet: A Randomized Clinical Trial. ( Ma, J; Pei, F; Xie, J; Yao, H; Yue, C, 2016) |
| " The objective of this trial was to assess the efficacy and safety of intravenous (IV) administration combined with topical administration of TXA regarding postoperative blood loss and transfusion rates in patients treated with primary unilateral total hip arthroplasty." | 2.82 | Tranexamic Acid Administration in Primary Total Hip Arthroplasty: A Randomized Controlled Trial of Intravenous Combined with Topical Versus Single-Dose Intravenous Administration. ( Bin, S; Fuxing, P; Jing, Y; Pengde, K; Yi, Z; Zongke, Z, 2016) |
| " Moreover, TXA use is safe in terms of incidence of symptomatic DVT and TE." | 2.82 | Combined Administration of Systemic and Topical Tranexamic Acid for Total Knee Arthroplasty: Can It Be a Better Regimen and Yet Safe? A Randomized Controlled Trial. ( Jain, NP; Nisthane, PP; Shah, NA, 2016) |
| "Tranexamic acid was used to treat bleeding after spinal surgery." | 2.82 | Meta-Analysis of the Efficacy and Safety of Tranexamic Acid in Spinal Surgery. ( Bao, X; Chen, Y; Cheng, Q; Gao, Z; Lu, H; Wu, Z, 2022) |
| "Tranexamic acid can be effective at decreasing blood loss and transfusion requirements associated with total hip arthroplasty (THA), but few studies have compared the efficacy of different intravenous dosing regimes." | 2.82 | Single-dose tranexamic acid for reducing bleeding and transfusions in total hip arthroplasty: A double-blind, randomized controlled trial of different doses. ( Kang, P; Ma, J; Pei, F; Wang, C; Xie, J; Yue, C, 2016) |
| "No pulmonary embolism was observed and no significant differences were found in other complications between the 2 groups." | 2.82 | The Efficacy and Safety of Combination of Intravenous and Topical Tranexamic Acid in Revision Hip Arthroplasty: A Randomized, Controlled Trial. ( Cao, F; Shen, B; Si, HB; Wu, YG; Yang, TM; Zeng, Y, 2016) |
| "No deep vein thrombosis was detected through Doppler ultrasound examination." | 2.80 | The reduction in blood loss with intra-articular injection of tranexamic acid in unilateral total knee arthroplasty without operative drains: a randomized controlled trial. ( Ding, PJ; Li, J; Lv, YM; Yang, Y; Ying-Ze, Z, 2015) |
| "No symptomatic deep vein thrombosis or pulmonary embolism was found in all patients." | 2.79 | Clinical value of tranexamic acid in unilateral and simultaneous bilateral TKAs under a contemporary blood-saving protocol: a randomized controlled trial. ( Chang, CB; Kang, YG; Kim, TK; Lee, JH; Lee, SH; Seo, ES; Yun, JH, 2014) |
| "No patient in either group developed deep vein thrombosis or pulmonary embolism up to 3 months." | 2.75 | Effects of tranexamic acid on blood loss during total hip arthroplasty. ( Ballal, MS; Denn, PG; Mitchell, P; Singh, J, 2010) |
| "Tranexamic acid is a fibrinolytic inhibitor which reduces blood loss in total knee replacement." | 2.74 | The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. ( Ahmad, M; Biant, LC; Field, RE; Rajesparan, K, 2009) |
| "Oral tranexamic acid (TXA) has been demonstrated to reduce the blood loss in primary total knee and hip arthroplasty, but the optimal regimen of oral TXA administration is still unknown." | 2.66 | The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial. ( Li, XL; Liu, WF; Liu, Y; Shao, J; Ye, W, 2020) |
| "Secondary outcomes were length of stay, deep venous thrombosis (DVT) and/or pulmonary embolism (PE)." | 2.61 | Transfusions and cost-benefit of oral versus intravenous tranexamic acid in primary total hip arthroplasty: A meta-analysis of randomized controlled trials. ( Chen, H; Ji, M; Liu, W; Tang, J; Wang, N; Xiong, X; Xu, L; Yang, T; Yang, Y, 2019) |
| "Tranexamic acid (TXA) is an anti-fibrinolytic agent successfully preventing blood loss when using intravenously (IV) in total hip arthroplasty (THA) and total knee arthroplasty (TKA)." | 2.58 | Efficacy and safety of oral compared with intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty: a meta-analysis. ( Gong, G; Han, N; Han, X; Liu, M, 2018) |
| "Tranexamic acid (TA) is a potent drug to reduce surgical blood loss in surgery, therefore, as a potential drug for application in THA." | 2.55 | Efficacy and safety of tranexamic acid in total hip replacement: A PRISMA-compliant meta-analysis of 25 randomized controlled trials. ( Hu, Y; Lei, P; Su, W; Zeng, M; Zhu, J; Zhu, Y, 2017) |
| " Secondary outcomes were other adverse events, blood transfusion, and blood loss." | 2.55 | The Safety and Efficacy of Lysine Analogues in Cancer Patients: A Systematic Review and Meta-Analysis. ( Breau, RH; Cagiannos, I; Cnossen, S; Fergusson, DA; Fergusson, NA; Hutton, B; Lavallée, LT; Montroy, J; Morash, C, 2017) |
| "Tranexamic acid (TXA) has been reported to reduce perioperative blood loss in hip joint arthroplasty." | 2.53 | Intravenous versus topical tranexamic acid in primary total hip replacement: A meta-analysis. ( Chen, P; Fang, Y; He, J; Liang, Y; Wang, J; Zhang, P, 2016) |
| " To further investigate the safe and effective role of using tranexamic acid (TA) in reducing transfusion rate and blood loss in total knee arthroplasty." | 2.52 | Safety and Efficacy of Tranexamic Acid in Total Knee Arthroplasty. ( Li, W; Liu, J; Qiu, Y; Xu, P; Yu, X; Zhu, Y, 2015) |
| "Meanwhile TA is recommended to reduce deep vein thrombosis and pulmonary embolism following TKA." | 2.49 | Use of intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials. ( Chen, C; Fu, DJ; Guo, L; Yang, L, 2013) |
| "The meta-analysis shows that the use of tranexamic acid for patients undergoing total knee arthroplasty is effective and safe for the reduction of blood loss." | 2.48 | Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. ( Chen, WP; Wu, LD; Yang, ZG, 2012) |
| " A total of 19 trials were eligible: 18 used intravenous administration, one also evaluated oral dosing and one trial evaluated topical use." | 2.47 | Tranexamic acid in total knee replacement: a systematic review and meta-analysis. ( Alshryda, S; Blenkinsopp, J; Mason, JM; Nargol, A; Sarda, P; Sukeik, M, 2011) |
| " To date, the most efficacious dosing protocol in this setting has not yet been ascertained." | 1.72 | No Difference in Blood Loss and Risk of Transfusion Between Patients Treated with One or Two Doses of Intravenous Tranexamic Acid After Simultaneous Bilateral TKA. ( Bugbee, WD; Copp, SN; Evans, AS; Ezzet, KA; McCauley, JC; Rosen, AS; Walker, RH; Wilde, JM, 2022) |
| "Tranexamic acid (TXA) has been shown to reduce blood loss and postoperative transfusions in total knee arthroplasty (TKA)." | 1.62 | One Versus Two Doses of Intravenous Tranexamic Acid in Total Knee Arthroplasty. ( Bernstein, JA; Charette, RS; Kamath, AF; Nchako, CM; Nelson, CL; Sloan, M, 2021) |
| "The incidence of deep vein thrombosis in the topical group (1." | 1.51 | Comparison of three routes of administration of tranexamic acid in primary unilateral total knee arthroplasty: Analysis of a national database. ( Hu, Q; Huang, Z; Pei, F; Xie, J; Zhou, Z, 2019) |
| "This study demonstrated that intra-articular 1 g TXA administration during TKA is safe and effective for reducing blood loss and blood transfusion without increasing VTE risk." | 1.51 | Intra-articular 1 g tranexamic acid administration during total knee arthroplasty is safe and effective for the reduction of blood loss and blood transfusion. ( Furumatsu, T; Hino, T; Kamatsuki, Y; Kodama, Y; Masuda, S; Miyazawa, S; Okazaki, Y; Ozaki, T, 2019) |
| "Tranexamic acid (TXA) has been shown to significantly reduce transfusion rates in primary total hip arthroplasties (THAs), but high-quality evidence is limited in the revision setting." | 1.51 | Intravenous tranexamic acid safely and effectively reduces transfusion rates in revision total hip arthroplasty. ( Abdel, MP; Amundson, AW; Hernandez, NM; Hines, JT; Pagnano, MW; Sierra, RJ, 2019) |
| "Tranexamic acid was administered during 62% of the arthroplasties in the ATT+ group and to 90% in the ATT- group." | 1.48 | Tranexamic acid use and risk of thrombosis in regular users ofantithrombotics undergoing primary total knee arthroplasty: a prospectivecohort study. ( Fennema, P; Hourlier, H, 2018) |
| "Tranexamic acid was not used perioperatively." | 1.46 | Prevalence of Venous Thromboembolic Events Is Low in Asians After Total Knee Arthroplasty Without Chemoprophylaxis. ( Bin Abd Razak, HR; Binte Abd Razak, NF; Tan, HA, 2017) |
| "VTE recurrence was not significantly greater in those who received TXA (2." | 1.46 | Tranexamic Acid Was Safe in Arthroplasty Patients With a History of Venous Thromboembolism: A Matched Outcome Study. ( Abdel, MP; Amundson, AW; Larson, DR; Pagnano, MW; Sabbag, OD, 2017) |
| "For the TXA+ group, 0." | 1.46 | Low Risk of Thromboembolic Events After Routine Administration of Tranexamic Acid in Hip and Knee Arthroplasty. ( Husted, H; Kallemose, T; Madsen, RV; Nielsen, CS; Troelsen, A, 2017) |
| "Melasma is a common pigmentary disorder among Asians and treatment is challenging." | 1.43 | Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. ( Goh, CL; Lee, HC; Thng, TG, 2016) |
| "There were no deep venous thrombosis or thromboembolic complications in any group." | 1.43 | A comparative, retrospective study of peri-articular and intra-articular injection of tranexamic acid for the management of postoperative blood loss after total knee arthroplasty. ( Dai, K; Mao, Z; Wang, Y; Yan, M; Yue, B, 2016) |
| "Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA." | 1.43 | Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016) |
| "The incidence of symptomatic deep vein thrombosis and pulmonary embolism was evaluated." | 1.43 | Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis. ( Chen, AF; Heller, S; Parvizi, J; Secrist, E; Shahi, A, 2016) |
| "Tranexamic acid (TXA) has been used to reduce blood loss during total hip arthroplasty (THA), but its use could increase the risk of venous thromboembolic disease (VTE)." | 1.42 | Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis? ( Hamada, M; Nishihara, S, 2015) |
| "Tranexamic acid (TXA) has shown safety and efficacy in reducing blood loss associated with various surgical procedures." | 1.42 | Does Tranexamic Acid Reduce Blood Loss and Transfusion Requirements Associated With the Periacetabular Osteotomy? ( Baca, GR; Clohisy, JC; Keith, AD; Schoenecker, PL; Wingerter, SA, 2015) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin." | 1.42 | Single perioperative dose of tranexamic acid in primary hip and knee arthroplasty. ( George, DA; Nwaboku, H; Sarraf, KM, 2015) |
| "Tranexamic acid was effective in reducing the need for blood transfusions while not increasing the risk of complications, including thromboembolic events and renal failure." | 1.40 | Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. ( Boettner, F; Danninger, T; Mazumdar, M; Memtsoudis, SG; Opperer, M; Poeran, J; Rasul, R; Suzuki, S, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (7.83) | 29.6817 |
| 2010's | 82 (71.30) | 24.3611 |
| 2020's | 24 (20.87) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, MJ | 1 |
| Shin, JY | 1 |
| Yoon, C | 1 |
| Kim, TW | 1 |
| Chang, CB | 3 |
| Kang, SB | 1 |
| Wilde, JM | 1 |
| Copp, SN | 1 |
| Ezzet, KA | 1 |
| Rosen, AS | 1 |
| Walker, RH | 1 |
| McCauley, JC | 1 |
| Evans, AS | 1 |
| Bugbee, WD | 1 |
| Qu, W | 1 |
| Zhou, H | 1 |
| Tian, P | 2 |
| Qin, X | 1 |
| Zhang, Y | 2 |
| Shen, W | 1 |
| Zhang, D | 1 |
| Wu, X | 2 |
| Kong, Q | 1 |
| Wang, Y | 3 |
| Zhang, B | 1 |
| Feng, P | 1 |
| Wu, Y | 3 |
| Guo, C | 1 |
| Li, W | 3 |
| Bao, X | 1 |
| Lu, H | 1 |
| Gao, Z | 2 |
| Wu, Z | 1 |
| Chen, Y | 3 |
| Cheng, Q | 1 |
| Qi, MT | 1 |
| Wang, SY | 1 |
| Wang, LT | 1 |
| Chen, XW | 1 |
| Zhan, WH | 1 |
| Zhu, XF | 1 |
| Wang, H | 3 |
| Russo, RM | 1 |
| Lozano, R | 1 |
| Ruf, AC | 1 |
| Ho, JW | 1 |
| Strayve, D | 1 |
| Zakaluzny, SA | 1 |
| Keeney-Bonthrone, TP | 1 |
| Augustinus, S | 2 |
| Mulders, MAM | 2 |
| Gardenbroek, TJ | 2 |
| Goslings, JC | 2 |
| Joo, YB | 1 |
| Kim, YM | 1 |
| An, BK | 1 |
| Lee, CW | 1 |
| Kwon, ST | 1 |
| Song, JH | 1 |
| Luan, H | 1 |
| Liu, K | 1 |
| Peng, C | 1 |
| Tian, Q | 1 |
| Song, X | 1 |
| Zheng, C | 1 |
| Ma, J | 4 |
| Xu, J | 1 |
| Li, M | 2 |
| Wu, L | 1 |
| Liu, Y | 5 |
| Shen, B | 3 |
| Xiao, C | 1 |
| Yu, W | 1 |
| Yao, K | 1 |
| Cao, Y | 1 |
| Long, N | 1 |
| Zhang, S | 1 |
| Jiang, Y | 1 |
| Gibbs, VN | 1 |
| Geneen, LJ | 1 |
| Champaneria, R | 1 |
| Raval, P | 1 |
| Dorée, C | 1 |
| Brunskill, SJ | 1 |
| Novak, A | 1 |
| Palmer, AJ | 1 |
| Estcourt, LJ | 1 |
| Yang, YZ | 1 |
| Cheng, QH | 1 |
| Zhang, AR | 1 |
| Yang, X | 1 |
| Zhang, ZZ | 1 |
| Guo, HZ | 1 |
| Knowlton, LM | 1 |
| Arnow, K | 1 |
| Trickey, AW | 1 |
| Sauaia, A | 1 |
| Knudson, MM | 1 |
| Zhang, Q | 1 |
| Zhao, L | 1 |
| Yu, Z | 1 |
| Guo, JJ | 1 |
| King, L | 1 |
| Randle, R | 1 |
| Dare, W | 1 |
| Bernaitis, N | 1 |
| Gerstein, NS | 1 |
| Cushnyr, BW | 1 |
| Petersen, TR | 1 |
| Siegel, D | 1 |
| Charette, RS | 1 |
| Bernstein, JA | 1 |
| Sloan, M | 1 |
| Nchako, CM | 1 |
| Kamath, AF | 1 |
| Nelson, CL | 1 |
| Jules-Elysee, KM | 1 |
| Tseng, A | 1 |
| Sculco, TP | 1 |
| Baaklini, LR | 1 |
| McLawhorn, AS | 1 |
| Pickard, AJ | 1 |
| Qin, W | 1 |
| Cross, JR | 1 |
| Su, EP | 1 |
| Fields, KG | 1 |
| Mayman, DJ | 1 |
| Li, J | 2 |
| Wang, L | 1 |
| Bai, T | 1 |
| Huang, Y | 1 |
| Yang, L | 2 |
| Jia, X | 1 |
| Yang, J | 1 |
| Kang, J | 1 |
| Ye, W | 1 |
| Liu, WF | 1 |
| Li, XL | 1 |
| Shao, J | 1 |
| Sun, C | 1 |
| Zhang, X | 3 |
| Chen, L | 1 |
| Deng, J | 1 |
| Ma, Q | 1 |
| Cai, X | 1 |
| Yang, H | 1 |
| Ma, H | 1 |
| Long, X | 1 |
| Xu, Z | 1 |
| Chen, X | 3 |
| He, T | 1 |
| Wang, W | 2 |
| Liu, L | 1 |
| Liu, X | 1 |
| Sentilhes, L | 1 |
| Sénat, MV | 1 |
| Le Lous, M | 1 |
| Winer, N | 1 |
| Rozenberg, P | 1 |
| Kayem, G | 1 |
| Verspyck, E | 1 |
| Fuchs, F | 1 |
| Azria, E | 1 |
| Gallot, D | 1 |
| Korb, D | 1 |
| Desbrière, R | 1 |
| Le Ray, C | 1 |
| Chauleur, C | 1 |
| de Marcillac, F | 1 |
| Perrotin, F | 1 |
| Parant, O | 1 |
| Salomon, LJ | 1 |
| Gauchotte, E | 1 |
| Bretelle, F | 1 |
| Sananès, N | 1 |
| Bohec, C | 1 |
| Mottet, N | 1 |
| Legendre, G | 1 |
| Letouzey, V | 1 |
| Haddad, B | 1 |
| Vardon, D | 1 |
| Madar, H | 1 |
| Mattuizzi, A | 1 |
| Daniel, V | 1 |
| Regueme, S | 1 |
| Roussillon, C | 1 |
| Benard, A | 1 |
| Georget, A | 1 |
| Darsonval, A | 1 |
| Deneux-Tharaux, C | 1 |
| Montroy, J | 1 |
| Fergusson, NA | 1 |
| Hutton, B | 1 |
| Lavallée, LT | 1 |
| Morash, C | 1 |
| Cagiannos, I | 1 |
| Cnossen, S | 1 |
| Fergusson, DA | 1 |
| Breau, RH | 1 |
| Liu, WB | 1 |
| Li, ZJ | 1 |
| Xu, GJ | 2 |
| Huang, YT | 1 |
| Ma, XL | 2 |
| Wang, J | 3 |
| Wang, Q | 4 |
| Dai, WL | 1 |
| Zhou, AG | 1 |
| Zhang, H | 1 |
| Zhang, J | 1 |
| Yozawa, S | 1 |
| Ogawa, H | 1 |
| Matsumoto, K | 1 |
| Akiyama, H | 1 |
| Wang, Z | 1 |
| Shen, X | 1 |
| Kim, YH | 3 |
| Park, JW | 3 |
| Kim, JS | 3 |
| Seo, DH | 1 |
| Zhu, J | 1 |
| Zhu, Y | 2 |
| Lei, P | 1 |
| Zeng, M | 1 |
| Su, W | 1 |
| Hu, Y | 1 |
| Liao, L | 1 |
| Tang, Q | 1 |
| Chen, YY | 1 |
| Wang, WC | 1 |
| Tian, S | 1 |
| Shen, Z | 1 |
| Peng, A | 1 |
| Liu, Q | 1 |
| Geng, P | 1 |
| Shi, L | 1 |
| Wang, P | 1 |
| Lei, Y | 1 |
| Huang, Q | 1 |
| Huang, Z | 3 |
| Xie, J | 5 |
| Chen, G | 1 |
| Pei, F | 5 |
| Palanisamy, JV | 1 |
| Das, S | 1 |
| Moon, KH | 1 |
| Kim, DH | 1 |
| Kim, TK | 3 |
| Fraval, A | 1 |
| Duncan, S | 1 |
| Murray, T | 1 |
| Duggan, J | 1 |
| Tirosh, O | 1 |
| Tran, P | 1 |
| Xiong, H | 1 |
| Zeng, Y | 2 |
| Wang, D | 1 |
| Wang, HY | 1 |
| Cao, C | 1 |
| Li, LL | 1 |
| Meng, WK | 1 |
| Pei, FX | 1 |
| Li, DH | 1 |
| Zhou, ZK | 1 |
| Zeng, WN | 1 |
| Pandey, K | 1 |
| Myers, SP | 1 |
| Kutcher, ME | 1 |
| Rosengart, MR | 1 |
| Sperry, JL | 1 |
| Peitzman, AB | 1 |
| Brown, JB | 1 |
| Neal, MD | 1 |
| Hu, Q | 1 |
| Zhou, Z | 2 |
| Han, X | 1 |
| Gong, G | 1 |
| Han, N | 1 |
| Liu, M | 2 |
| Yu, CC | 1 |
| Kadri, O | 1 |
| Kadado, A | 1 |
| Buraimoh, M | 1 |
| Pawloski, J | 1 |
| Bartol, S | 1 |
| Graziano, G | 1 |
| Dibiasi, C | 1 |
| Wiegele, M | 1 |
| Gratz, J | 1 |
| Wang, N | 1 |
| Xiong, X | 1 |
| Xu, L | 1 |
| Ji, M | 1 |
| Yang, T | 1 |
| Tang, J | 1 |
| Yang, Y | 2 |
| Liu, W | 1 |
| Chen, H | 1 |
| Zheng, F | 1 |
| Zheng, Z | 1 |
| Wu, C | 1 |
| Hines, JT | 1 |
| Hernandez, NM | 1 |
| Amundson, AW | 2 |
| Pagnano, MW | 2 |
| Sierra, RJ | 1 |
| Abdel, MP | 2 |
| Kamatsuki, Y | 1 |
| Miyazawa, S | 1 |
| Furumatsu, T | 1 |
| Kodama, Y | 1 |
| Hino, T | 1 |
| Okazaki, Y | 2 |
| Masuda, S | 1 |
| Ozaki, T | 1 |
| Fu, DJ | 1 |
| Chen, C | 1 |
| Guo, L | 1 |
| Koh, IJ | 1 |
| Kang, YG | 1 |
| Seo, ES | 1 |
| Lee, JH | 1 |
| Yun, JH | 1 |
| Lee, SH | 1 |
| Georgiadis, AG | 1 |
| Muh, SJ | 1 |
| Silverton, CD | 1 |
| Weir, RM | 1 |
| Laker, MW | 1 |
| Huang, F | 1 |
| Wu, D | 1 |
| Ma, G | 1 |
| Yin, Z | 1 |
| Chen, JY | 2 |
| Rikhraj, IS | 1 |
| Tay, DK | 2 |
| Chin, PL | 2 |
| Chia, SL | 2 |
| Lo, NN | 2 |
| Yeo, SJ | 2 |
| George, DA | 1 |
| Sarraf, KM | 1 |
| Nwaboku, H | 1 |
| Lv, YM | 1 |
| Ding, PJ | 1 |
| Ying-Ze, Z | 1 |
| Alshryda, S | 2 |
| Sukeik, M | 2 |
| Sarda, P | 2 |
| Blenkinsopp, J | 2 |
| Haddad, FS | 1 |
| Mason, JM | 2 |
| Poeran, J | 1 |
| Rasul, R | 1 |
| Suzuki, S | 1 |
| Danninger, T | 1 |
| Mazumdar, M | 1 |
| Opperer, M | 1 |
| Boettner, F | 1 |
| Memtsoudis, SG | 1 |
| Wang, C | 2 |
| Han, Z | 1 |
| Ma, JX | 1 |
| Jiang, X | 1 |
| Xie, S | 1 |
| Wang, K | 1 |
| Nishihara, S | 1 |
| Hamada, M | 1 |
| Yue, C | 3 |
| Yang, P | 1 |
| Kang, P | 2 |
| Wingerter, SA | 1 |
| Keith, AD | 1 |
| Schoenecker, PL | 1 |
| Baca, GR | 1 |
| Clohisy, JC | 1 |
| Wei, Z | 1 |
| Zhang, W | 1 |
| Bai, G | 1 |
| Zhang, C | 1 |
| Lin, J | 1 |
| Yu, X | 2 |
| Xu, P | 1 |
| Liu, J | 1 |
| Qiu, Y | 1 |
| Jain, NP | 1 |
| Nisthane, PP | 1 |
| Shah, NA | 1 |
| Sharfman, ZT | 1 |
| Campbell, JC | 1 |
| Mirocha, JM | 1 |
| Spitzer, AI | 1 |
| Chen, S | 1 |
| Wu, K | 1 |
| Kong, G | 1 |
| Feng, W | 1 |
| Deng, Z | 1 |
| Heller, S | 1 |
| Secrist, E | 1 |
| Shahi, A | 1 |
| Chen, AF | 1 |
| Parvizi, J | 1 |
| Sargant, N | 1 |
| Roy, A | 1 |
| Simpson, S | 1 |
| Chandrakumaran, K | 1 |
| Alves, S | 1 |
| Coakes, J | 1 |
| Bell, J | 1 |
| Knight, J | 1 |
| Wilson, P | 1 |
| Mohamed, F | 1 |
| Cecil, T | 1 |
| Moran, B | 1 |
| Stowers, MD | 1 |
| Munro, JT | 1 |
| Hill, AG | 1 |
| Wu, YG | 1 |
| Yang, TM | 1 |
| Si, HB | 1 |
| Cao, F | 1 |
| Lee, HC | 1 |
| Thng, TG | 1 |
| Goh, CL | 1 |
| Moskal, JT | 1 |
| Capps, SG | 1 |
| Yao, H | 1 |
| Sun, X | 1 |
| Dong, Q | 1 |
| Zhang, YG | 1 |
| Yi, Z | 1 |
| Bin, S | 1 |
| Jing, Y | 1 |
| Zongke, Z | 1 |
| Pengde, K | 1 |
| Fuxing, P | 1 |
| Gao, F | 1 |
| Sun, W | 1 |
| Guo, W | 1 |
| Li, Z | 1 |
| Shin, YS | 1 |
| Yoon, JR | 1 |
| Lee, HN | 1 |
| Park, SH | 2 |
| Lee, DH | 1 |
| Pinsornsak, P | 1 |
| Rojanavijitkul, S | 1 |
| Chumchuen, S | 1 |
| Wang, JW | 1 |
| Chen, B | 1 |
| Lin, PC | 1 |
| Yen, SH | 1 |
| Huang, CC | 1 |
| Kuo, FC | 1 |
| Weng, K | 1 |
| Bi, Q | 1 |
| Zhao, C | 1 |
| Hourlier, H | 1 |
| Fennema, P | 1 |
| Mao, Z | 1 |
| Yue, B | 1 |
| Yan, M | 1 |
| Dai, K | 1 |
| Bin Abd Razak, HR | 1 |
| Binte Abd Razak, NF | 1 |
| Tan, HA | 1 |
| Madsen, RV | 1 |
| Nielsen, CS | 1 |
| Kallemose, T | 1 |
| Husted, H | 1 |
| Troelsen, A | 1 |
| Sun, Q | 1 |
| Wu, J | 1 |
| Ge, W | 1 |
| Cai, M | 1 |
| Li, S | 1 |
| Zhang, XQ | 1 |
| Ni, J | 1 |
| Ge, WH | 1 |
| Zhang, P | 2 |
| Liang, Y | 2 |
| Chen, P | 2 |
| Fang, Y | 2 |
| He, J | 2 |
| Sabbag, OD | 1 |
| Larson, DR | 1 |
| Ghosh, K | 2 |
| Escher, R | 1 |
| Rajesparan, K | 1 |
| Biant, LC | 1 |
| Ahmad, M | 1 |
| Field, RE | 1 |
| Madrid, C | 1 |
| Sanz, M | 1 |
| Singh, J | 1 |
| Ballal, MS | 1 |
| Mitchell, P | 1 |
| Denn, PG | 1 |
| Onodera, T | 1 |
| Majima, T | 1 |
| Sawaguchi, N | 1 |
| Kasahara, Y | 1 |
| Ishigaki, T | 1 |
| Minami, A | 1 |
| Kerros, H | 1 |
| Roule, V | 1 |
| Ivascau, C | 1 |
| Labombarda, F | 1 |
| Nargol, A | 1 |
| Mihalache, RM | 1 |
| Ames, PR | 1 |
| Yang, ZG | 1 |
| Chen, WP | 1 |
| Wu, LD | 1 |
| Seo, JG | 1 |
| Moon, YW | 1 |
| Kim, SM | 1 |
| Ko, KR | 1 |
| Zohar, E | 1 |
| Ellis, M | 1 |
| Ifrach, N | 1 |
| Stern, A | 1 |
| Sapir, O | 1 |
| Fredman, B | 1 |
| Huvers, F | 1 |
| Slappendel, R | 1 |
| Benraad, B | 1 |
| van Hellemondt, G | 1 |
| van Kraaij, M | 1 |
| Orpen, NM | 1 |
| Little, C | 1 |
| Walker, G | 1 |
| Crawfurd, EJ | 1 |
| Molenaar, IQ | 1 |
| Warnaar, N | 1 |
| Groen, H | 1 |
| Tenvergert, EM | 1 |
| Slooff, MJ | 1 |
| Porte, RJ | 1 |
| Berntorp, E | 1 |
| Follrud, C | 1 |
| Lethagen, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Multicenter, Randomized, Parallel Groups Study Comparing the Safety and the Efficacy of the Administration of One Intra-articular Injection of 4.8 ml (HO-1) or Three Intra-articular Injections of 2.2 ml (HS-3) of Pandora Gel to One Intra-arti[NCT05978180] | 252 participants (Anticipated) | Interventional | 2023-10-18 | Recruiting | |||
| Prospective, Multicenter, Open Study Evaluating the Short-term Safety of Use of Pandora Administered in the Form of 1 Intra-articular Injection of Happyone or 3 Intra-articular Injections of Happysoft in Patients Suffering From Gonarthrosis[NCT05414617] | 20 participants (Actual) | Interventional | 2022-06-08 | Completed | |||
| Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage[NCT05554211] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-07-12 | Recruiting | ||
| Precise Application of Topical Tranexamic Acid to Enhance Endoscopic Hemostasis for Peptic Ulcer Bleeding: A Randomized Controlled Study[NCT05248321] | 60 participants (Actual) | Interventional | 2022-03-24 | Completed | |||
| Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial[NCT01658124] | Phase 3 | 12,009 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery :a Multicenter Randomised, Double Blind Placebo Controlled Trial (TRAAP2)[NCT03431805] | Phase 3 | 4,574 participants (Actual) | Interventional | 2018-03-03 | Completed | ||
| Postoperative Drainage in Total Knee Arthroplasty in the Presence of Tranexamic Acid: a Clinical Trial[NCT03915756] | 42 participants (Anticipated) | Interventional | 2019-08-22 | Recruiting | |||
| The Effects of the Timing of Tranexamic Acid Administration on Blood Loss in Hip Fractures.[NCT04488367] | Early Phase 1 | 120 participants (Anticipated) | Interventional | 2020-07-06 | Recruiting | ||
| Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss, Transfusion Index and Complications After Total Hip Replacement. A Prospective, Randomized, Double Blind Clinical Trial[NCT04187014] | Phase 2 | 90 participants (Actual) | Interventional | 2020-02-06 | Completed | ||
| Effect of no Drainage Tube on Blood Loss and Recovery After High Tibial Osteotomy[NCT03954860] | 80 participants (Actual) | Interventional | 2018-08-01 | Completed | |||
| Evaluation of the Use of Tranexamic Acid in Tibial Osteotomies: a Randomised Controlled Clinical Trial.[NCT04785651] | 84 participants (Anticipated) | Interventional | 2021-02-22 | Recruiting | |||
| Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty[NCT03825939] | Phase 4 | 52 participants (Actual) | Interventional | 2015-04-21 | Terminated (stopped due to Lack of patient enrollment due to only one surgeon that was enrolling.) | ||
| Single Centre Randomised Controlled Trial to Assess the Effect of the Addition of Twenty-four Hours of Oral Tranexamic Acid Post-operatively to a Single Intra-operative Intravenous Dose of Tranexamic Acid on Calculated Blood Loss Following Primary Hip and[NCT03690037] | Phase 4 | 1,089 participants (Actual) | Interventional | 2016-07-07 | Completed | ||
| Comparison of the Effect of Two Common Regimens of Administration of Tranexamic Acid on Hemostasis and Clinical Outcome of Patients Undergoing Total Knee Arthroplasty[NCT04443920] | Phase 4 | 86 participants (Actual) | Interventional | 2019-10-29 | Completed | ||
| Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty[NCT03328832] | Phase 4 | 70 participants (Actual) | Interventional | 2017-09-12 | Completed | ||
| Blood Loss Reduction After Total Knee Arthroplasty. A Comparison Between Topical Tranexamic Acid and Platelet Rich Plasma: Controlled Clinical Trial[NCT02650856] | Phase 3 | 40 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Blood-saving Effect of Kaolin-based Hemostatic Gauze Combined With Intravenous Tranexamic Acid in Total Knee Arthroplasty[NCT05504577] | Phase 4 | 120 participants (Anticipated) | Interventional | 2022-03-16 | Recruiting | ||
| Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty[NCT02453802] | Phase 4 | 90 participants (Anticipated) | Interventional | 2015-06-30 | Not yet recruiting | ||
| Comparison of Topical Tranexamic Acid and Floseal® on Blood Loss After Total Knee Arthroplasty in Patients With a Thromboembolic Risk[NCT02865174] | Phase 4 | 90 participants (Anticipated) | Interventional | 2016-09-30 | Not yet recruiting | ||
| The Use of Tranexamic Acid in Irrigation Fluid to Improve Arthroscopic Visualization in Shoulder Surgery: A Randomized Controlled Trial[NCT04594408] | Phase 4 | 128 participants (Actual) | Interventional | 2020-09-01 | Active, not recruiting | ||
| Prophylactic Use of Topical Tranexamic Acid to Aid Surgical Haemostasis During Caesarean Sections in Parturients With Moderate to High Risk of Bleeding[NCT02492087] | Phase 3 | 84 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| The Use of Tranexamic Acid to Reduce the Need for Transfusion 1 Week Post-operatively for Hemiarthroplasty or Intramedullary Nailing Needed to Correct Acute Hip Fractures[NCT02947529] | Phase 4 | 113 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Prospective Randomized Study Comparing Topical Versus Intravenous Tranexamic Acid in Anterior Total Hip Arthroplasty[NCT03359525] | Phase 4 | 114 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| The Effect of Tranexamic Acid (TXA) on Blood Loss and Transfusion Rates in Burn Wound Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial[NCT02753816] | 25 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to Study enrollment and goals unable to be reached.) | |||
| Local Injection of Tranexamic Acid May Reduce Bleeding, Injection Pain, and Other Post-op Complications During Mohs Micrographic Surgery[NCT04630886] | Early Phase 1 | 200 participants (Anticipated) | Interventional | 2021-06-16 | Enrolling by invitation | ||
| The Effectiveness Of Intravenous Tranexamic Acid (TXA) on Reducing Perioperative Blood Loss For Patients Undergoing Periacetabular Osteotomy (PAO): A Randomized Double Blind Placebo Controlled Trial[NCT03823417] | Phase 4 | 0 participants (Actual) | Interventional | 2019-07-31 | Withdrawn (stopped due to Investigators decided not to begin the study.) | ||
| Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
| The Comparative Efficacy of Peri-articular and Intraarticular Tranexamic Acid in Total Knee Arthroplasty: A Prospective, Double-Blind Randomized, Controlled Trial[NCT03074994] | Phase 2 | 108 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| Efficacy of Tranexamic Acid in Femoral Shaft Fractures Osteosynthesis; A Double Blind Randomized Controlled Trial[NCT04803591] | Phase 4 | 0 participants (Actual) | Interventional | 2021-08-01 | Withdrawn (stopped due to Not approved by Ethics Commettee) | ||
| Blood-saving Effect of Combined Intravenous Tranexamic Acid With Topical Floseal® Application, a Comparison With Intravenous Tranexamic Acid Only in Total Hip Arthroplasty[NCT03623789] | Phase 4 | 90 participants (Anticipated) | Interventional | 2018-08-15 | Recruiting | ||
| The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans[NCT04233749] | Phase 2 | 5 participants (Anticipated) | Interventional | 2020-03-17 | Recruiting | ||
| Tissue-resident Memory T Cells Expression in Melasma[NCT05698342] | 20 participants (Actual) | Observational | 2021-07-01 | Completed | |||
| Do Peri-operative High Doses of Intravenous Glucocorticoids Improve Short-term Functional Outcome After Direct Anterior Total Hip Arthroplasty? A Randomized, Single Surgeon, Placebo Controlled, Double Blind Study[NCT04317872] | 70 participants (Anticipated) | Interventional | 2020-07-01 | Recruiting | |||
| Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty: A Randomized Controlled Trial[NCT02829346] | Phase 2 | 60 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630] | Phase 3 | 130 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Role of Topical Tranexamic Acid in Total Hip Arthroplasty[NCT01866943] | Phase 2 | 41 participants (Actual) | Interventional | 2011-11-30 | Terminated | ||
| The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery[NCT02684851] | Phase 3 | 87 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Evaluation of Tranexamic Acid Prior to Surgery in the Geriatric Hip Fracture Population for the Reduction of Post-Operative Blood Transfusion[NCT03923959] | Phase 3 | 400 participants (Anticipated) | Interventional | 2020-02-01 | Active, not recruiting | ||
| Efficacy of Local Hemostatic Management in Implant Surgery in Anticoagulated Patients on Warfarin: a Randomized Clinical Study[NCT04846114] | 71 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Evaluation of Efficacy and Safety of Perioperative Tranexamic Acid During Primary Total Knee Arthroplasty: A Randomized, Clinical Trial[NCT05919615] | 100 participants (Actual) | Interventional | 2021-07-15 | Completed | |||
| Intravenous Tranexamic Acid to Reduce Blood Loss in Reverse Total Shoulder Arthroplasty[NCT02043132] | Phase 2/Phase 3 | 116 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients: A Randomized Controlled Study[NCT03109652] | Phase 4 | 144 participants (Anticipated) | Interventional | 2017-07-10 | Recruiting | ||
| Tranexamic Acid in Knee Joint Surgery - a Randomised Controlled Trial[NCT02278263] | Phase 4 | 150 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Investigation of the Blood Sparing Properties of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty[NCT02569658] | 110 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| The Combined Efficacy of Evicel and Tranexamic Acid on Total Knee Arthroplasty During the Early Perioperative Period[NCT02553122] | Phase 3 | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to Data has been published on this study (this would have been a duplicate study)) | ||
| Effects on Bleeding in Knee Arthroplasty After Ischemic Preconditioning With Sevoflurane[NCT03379103] | 30 participants (Actual) | Interventional | 2018-02-02 | Completed | |||
| Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement; A Prospective Triple-blinded Randomized Controlled Trial.[NCT01850394] | 152 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831] | Early Phase 1 | 71 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measured in Days (NCT03825939)
Timeframe: At Hospital Discharge
| Intervention | Days (Mean) |
|---|---|
| Intravenous Tranexamic Acid | 3 |
| Intravenous Placebo | 3 |
| Intravenous Tranexamic Acid Followed by Intravenous Placebo | 3 |
We will record the event of blood transfusion, and calculate the incidence of transfusion (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Topical TXA and Floseal | 1 |
| Topical TXA Alone | 0 |
The composite of any venous thromoembolism events, ischemic heart attacks, cerebrovascular accidents (NCT03328832)
Timeframe: within 30 days of the operation
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Topical TXA and Floseal | 0 |
| Topical TXA Alone | 0 |
Total blood loss was calculated according to Nadler et al., which used maximum postoperative reduction of the Hb level adjust for weight and height of the patient. The formula is as follows, Total blood loss = (Total blood volume x [change in Hb level / preoperative Hb level])x1000+volume transfused (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
| Intervention | ml (Mean) |
|---|---|
| Combined Topical TXA and Floseal | 678 |
| Topical TXA Alone | 733 |
The blood quantification will be taken at 6am every day. (NCT02650856)
Timeframe: up to 2nd day post operative (24 and 48 hrs)
| Intervention | mL (Mean) | |
|---|---|---|
| 24 hours | 48 hours | |
| Group 1 Tranexamic Acid | 246.4 | 120.8 |
| Group 2 Platelet Rich Plasma | 263.2 | 140.2 |
The blood test will be taken at 6am every day. Using the same laboratory parameters. (NCT02650856)
Timeframe: up to 3rd day post operative (Baseline, 24, 48 and 72hrs)
| Intervention | percentage of Hematocrite (Mean) | |||
|---|---|---|---|---|
| Baseline | 24 hours | 48 hours | 72 hours | |
| Group 1 Tranexamic Acid | 41.7 | 31.6 | 29.1 | 28.6 |
| Group 2 Platelet Rich Plasma | 41.5 | 29.8 | 27.7 | 27.3 |
The blood test will be taken at 6am every day. Using the same laboratory parameters. (NCT02650856)
Timeframe: up to 3rd day post operative (Baseline, 24, 48 and 72hrs)
| Intervention | g/dL (Mean) | |||
|---|---|---|---|---|
| Baseline | 24 hours | 48 hours | 72 hours | |
| Group 1 Tranexamic Acid | 13.6 | 10.3 | 9.5 | 9.3 |
| Group 2 Platelet Rich Plasma | 13.6 | 9.9 | 9.2 | 9.1 |
To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries. (NCT02753816)
Timeframe: First burn surgery to hospital discharge
| Intervention | Patients with 1 or more transfusions (Number) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 3 |
To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival. (NCT02753816)
Timeframe: Hospital admission to hospital discharge
| Intervention | Days (Median) |
|---|---|
| Tranexamic Acid | 23 |
| Placebo | 9 |
To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries. (NCT02753816)
Timeframe: Intraoperative, average 122 minutes
| Intervention | mL (Median) |
|---|---|
| Tranexamic Acid | 100 |
| Placebo | 325 |
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
| Intervention | grams per deciliter (Mean) |
|---|---|
| Tranexamic Acid | -1.8 |
| Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 3 |
| Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 35 |
| Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 108 |
| Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 233 |
| Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 892 |
| Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 20 |
| Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 29 |
| Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 649 |
| Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 12 |
| Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 339 |
| Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 201 |
| Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 162 |
| Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 0 |
Estimated Blood Loss defined as Pre Op Hgb mins the Post Op Day two Hgb. (NCT01866943)
Timeframe: Pre Op, Post Op Day 2
| Intervention | Hemoglobin (grams/deciliter) (Mean) |
|---|---|
| Baseline Population | 2.93 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 2 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 65.76 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 6 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 81.77 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: Preoperative
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 58.34 |
Measurement of the thigh at the half way point between the prominence of the greater trochanter and the lateral epicondyle of the femur. No data recorded at 2 weeks or 6 weeks for this study population. (NCT01866943)
Timeframe: Pre Op
| Intervention | centimeters (Mean) |
|---|---|
| Baseline Population | 52.99 |
Number of participant received allogenic blood transfusions. (NCT02684851)
Timeframe: post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 21 |
| Placebo | 13 |
To measure average estimate perioperative blood loss (NCT02684851)
Timeframe: perioperative
| Intervention | mL (Mean) |
|---|---|
| Tranexamic | 727.6 |
| Placebo | 560.1 |
Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo? (NCT02684851)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 1 |
| Placebo | 0 |
Average units packed red blood cells transfused among participants (NCT02684851)
Timeframe: perioperative
| Intervention | Units of packed red blood cells (Mean) |
|---|---|
| Tranexamic | 2.65 |
| Placebo | 2.36 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Deep venous thrombosis" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Hematoma" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Infection" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Myocardial infarction" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 1 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Pulmonary Embolism" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
Total Blood Loss as calculated according to method as described by Good et al. Total Blood Loss (mL) = 1000 X Hb(loss)/Hb(initial) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
| Intervention | Total Blood Loss (mL) (Mean) |
|---|---|
| Tranexamic Acid | 1122.4 |
| Normal Saline | 1472 |
Total Drain Output as measured postoperatively 0-48 hours (NCT02043132)
Timeframe: 0-48 hours postoperatively
| Intervention | mL (Mean) |
|---|---|
| Tranexamic Acid | 221 |
| Normal Saline | 372 |
Total hemoglobin loss estimated using the formula for total blood volume described by Nadler et al Hb(loss) = blood volume (L) x [Hb(initial)(g/L) - Hb(final)(g/L)] + Hb(transfused) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
| Intervention | g (Mean) |
|---|---|
| Tranexamic Acid | 154.6 |
| Normal Saline | 200.1 |
"The loss of haemoglobin (Hb) was then estimated according to the formula:~Hb(loss) = Blood volume (BV) x (Hbi-Hbe) x 0.001+Hbt~where Hb (loss) (g) is the amount of Hb lost, Hbi (g/L) the Hb concentration before surgery, Hbe (g/L) is the Hbe concentration on the third day after surgery, and Hbt (g) is the total amount of allogeneic Hb transfused. A unit of banked blood is considered to contain a minimum of 40g Hb (Blood component data sheet, New Zealand Blood Services [NZBS]). All units of blood are processed and stored in a nationally standardised manner. The blood loss (ml) was related to the patient's preoperative Hb value (g/L):~Blood loss =1000 x Hb(loss) /Hbi" (NCT02278263)
Timeframe: Post operative day 3
| Intervention | mls (Mean) |
|---|---|
| Control | 1090 |
| Intraarticular | 716 |
| Systemic | 746 |
Day of surgery is counted as Day 0. (NCT02278263)
Timeframe: Average length of stay is expected to be 3 to 5 days
| Intervention | days (Median) |
|---|---|
| Control | 4 |
| Topical | 4 |
| Systemic | 4 |
"Those patients receiving blood products. Standardised protocol is as follows:~The criterion for transfusion of blood products will be a haemoglobin < 80g/L or a haemoglobin <100g/L in a patient with ischaemic heart disease or with significant symptomatology" (NCT02278263)
Timeframe: Participants will be followed for the duration of their hospital stay expected to be an average of 3-5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 2 |
| Topical | 1 |
| Systemic | 0 |
Intravenous fluid (excluding blood transfusion) given during and first 24 hours after surgery (NCT02278263)
Timeframe: Day 1
| Intervention | mls (Mean) |
|---|---|
| Control | 1765 |
| Topical | 1613 |
| Systemic | 1807 |
Rates of deep vein thrombosis (DVT) and pulmonary embolus (PE) in each group recorded as a percentage (NCT02278263)
Timeframe: Postoperatively within 30 days after surgery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| DVT | PE | |
| Control | 0 | 0 |
| Systemic | 0 | 1 |
| Topical | 0 | 2 |
Range of motion measured in degrees on postoperative days 1-3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 57 | 71 | 75 |
| Systemic | 58 | 72 | 78 |
| Topical | 65 | 75 | 82 |
Range of motion measured in degrees for postoperative days 1 to 3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 65 | 76 | 82 |
| Systemic | 68 | 80 | 87 |
| Topical | 74 | 81 | 87 |
Must be diagnosed via ultrasound duplex (NCT02569658)
Timeframe: 30 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 1 |
Must be diagnosed via CT chest or V/Q lung scan (NCT02569658)
Timeframe: 30 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Must be diagnosed via CT scan or MRI (NCT02569658)
Timeframe: 30 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Patients who received a post-op transfusion of pack red blood cells (NCT02569658)
Timeframe: Average of 3 days post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Units of pack red blood cells that the patients recieved (NCT02569658)
Timeframe: Average of 3 days post-operatively
| Intervention | Units of PRBCs (Number) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Equated based on the patient's predicted blood volume and change in hemoglobin from the pre-operative level to the lowest post-operative level. (NCT02569658)
Timeframe: Average of 3 days post-operatively
| Intervention | mL (Mean) |
|---|---|
| Tranexamic Acid Group | 152.2 |
| Placebo Group | 178.0 |
(NCT01850394)
Timeframe: postoperative period (5 days after surgery)
| Intervention | participants (Number) |
|---|---|
| Control Group | 10 |
| TXA-250 Group | 6 |
| TXA-500 Group | 0 |
Total hemoglobin loos measured by difference between hemoglobin preoperatively and the fourth postoperative day (NCT01850394)
Timeframe: 5 days after surgery
| Intervention | g/dL (Mean) |
|---|---|
| Control Group | 2.9 |
| TXA-250 Group | 2.2 |
| TXA-500 Group | 2.2 |
"Knee function score was measured with 2 methods, and were evaluated preoperatively and then postoperatively at 3-month, 6-month, and 1-year period.~Knee Society Knee Score using for rating knee function measurement and subdivided into two parts; knee score and function score 1.1. Knee score : calculated from pain, presence of deformity, total range of flexion, alignment, and stability. Total score is 100 (0-100), more score means better.~1.2. Function score : calculated from patient's ability to walk and climb stairs. The score ranges from 0-100, more score means better.~Western Ontario and McMaster Universities Arthritis Index or WOMAC score : a widely used, standardized questionnaires for evaluating the condition of patients with knee osteoarthritis, including pain (score = 0-20), stiffness (0-8), and functional limitation (0-68). Total score ranges from 0-68, lower score means better." (NCT01850394)
Timeframe: 1 year after surgery
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Knee Society Knee score at 1 year | WOMAC score at 1 year | |
| Control Group | 148.9 | 15.5 |
| TXA-250 Group | 151.2 | 15.1 |
| TXA-500 Group | 150.9 | 14.5 |
"Postoperative complications were measured as an incidence of the following complications;~wound hematoma~surgical site infection~systemic infection~deep vein thrombosis~pulmonary embolism~knee stiffness requiring manipulation~medical complication such as myocardial infarction, congestive hear failure" (NCT01850394)
Timeframe: postoperative 1-year period
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Re-clamp incidence | Re-dressing incidence | Venous thromboembolic complication | Congestive heart failure | |
| Control Group | 6 | 3 | 4 | 0 |
| TXA-250 Group | 1 | 0 | 1 | 1 |
| TXA-500 Group | 0 | 0 | 2 | 0 |
"Drainage blood loss measured by accumulating total drainage volume postoperatively~Calculated total blood loss measured by using specific formula and difference between hematocrit preoperatively and the fourth postoperative day" (NCT01850394)
Timeframe: 5 days after surgery
| Intervention | ml (Median) | |
|---|---|---|
| Drainage blood loss | Calculated total blood loss | |
| Control Group | 546.9 | 329.2 |
| TXA-250 Group | 475.0 | 239.7 |
| TXA-500 Group | 430.2 | 217.2 |
41 reviews available for tranexamic acid and Deep Vein Thrombosis
| Article | Year |
|---|---|
Meta-Analysis of the Efficacy and Safety of Tranexamic Acid in Spinal Surgery.
Topics: Databases, Factual; Humans; Odds Ratio; PubMed; Tranexamic Acid; Venous Thrombosis | 2022 |
A Systematic Review of Tranexamic Acid-Associated Venous Thromboembolic Events in Combat Casualties and Considerations for Prolonged Field Care.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid; Venous Thromboembolism; Venous Thrombo | 2023 |
Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis.
Topics: Adult; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemiar | 2023 |
Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis.
Topics: Adult; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemiar | 2023 |
Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis.
Topics: Adult; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemiar | 2023 |
Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis.
Topics: Adult; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemiar | 2023 |
Efficacy and safety of tranexamic acid in posterior lumbar interbody fusion: a meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Randomized Controlled Trials as Topic; System | 2023 |
The Optimal Dose, Efficacy and Safety of Tranexamic Acid and Epsilon-Aminocaproic Acid to Reduce Bleeding in TKA: A Systematic Review and Bayesian Network Meta-analysis.
Topics: Administration, Intravenous; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2023 |
Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint replacement for hip, pelvic and long bone fractures.
Topics: Arthroplasty, Replacement; Fibrinogen; Fractures, Bone; Hemorrhage; Hemostatics; Humans; Myocardial | 2023 |
Efficacy and safety of single- and double-dose intravenous tranexamic acid in hip and knee arthroplasty: a systematic review and meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, | 2023 |
The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial.
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, S | 2020 |
Comparison of oral versus intravenous tranexamic acid in total knee and hip arthroplasty: A GRADE analysis and meta-analysis.
Topics: Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replace | 2020 |
The Safety and Efficacy of Lysine Analogues in Cancer Patients: A Systematic Review and Meta-Analysis.
Topics: Adult; Aminocaproic Acid; Blood Loss, Surgical; Blood Transfusion; Erythrocyte Transfusion; Humans; | 2017 |
The efficacy and safety of tranexamic acid in revision total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Length of St | 2017 |
Most Effective Regimen of Tranexamic Acid for Reducing Bleeding and Transfusions in Primary Total Knee Arthroplasty: A Meta-Analysis of Randomized Controlled Trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2018 |
The efficacy of combined intra-articular and intravenous tranexamic acid for blood loss in primary total knee arthroplasty: A meta-analysis.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2017 |
Efficacy and safety of tranexamic acid in total hip replacement: A PRISMA-compliant meta-analysis of 25 randomized controlled trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2017 |
Tranexamic acid plus drain-clamping can reduce blood loss in total knee arthroplasty: A systematic review and meta-analysis.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2018 |
Tranexamic acid versus aminocaproic acid for blood management after total knee and total hip arthroplasty: A systematic review and meta-analysis.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2018 |
The efficacy and safety of combined administration of intravenous and topical tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2018 |
Efficacy and safety of oral compared with intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty: a meta-analysis.
Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacemen | 2018 |
Transfusions and cost-benefit of oral versus intravenous tranexamic acid in primary total hip arthroplasty: A meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacemen | 2019 |
Oral vs intravenous tranexamic acid in total-knee arthroplasty and total hip arthroplasty: A systematic review and meta-analysis.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic | 2019 |
Use of intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2013 |
Practical issues for the use of tranexamic acid in total knee arthroplasty: a systematic review.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Dose-Response Relati | 2014 |
The use of tranexamic acid to reduce blood loss and transfusion in major orthopedic surgery: a meta-analysis.
Topics: Anti-Arrhythmia Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Humans; Orthopedic Pr | 2014 |
A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2014 |
Topical application of tranexamic acid in primary total hip arthroplasty: a systemic review and meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; | 2015 |
Effect of Topical Tranexamic Acid in Reducing Bleeding and Transfusions in TKA.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2015 |
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human | 2015 |
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human | 2015 |
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human | 2015 |
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human | 2015 |
Safety and Efficacy of Tranexamic Acid in Total Knee Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; D | 2015 |
The efficacy of topical tranexamic acid in total hip arthroplasty: a meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2016 |
The efficacy of topical tranexamic acid in total hip arthroplasty: a meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2016 |
The efficacy of topical tranexamic acid in total hip arthroplasty: a meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2016 |
The efficacy of topical tranexamic acid in total hip arthroplasty: a meta-analysis.
Topics: Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Hu | 2016 |
Intravenous versus topical tranexamic acid in primary total hip replacement: A systemic review and meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
Topical fibrin sealant versus intravenous tranexamic acid for reducing blood loss following total knee arthroplasty: A systematic review and meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
The effectiveness and safety of tranexamic acid in bilateral total knee arthroplasty: A meta-analysis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Female; Humans; M | 2016 |
Combined use of intravenous and topical versus intravenous tranexamic acid in primary total joint arthroplasty: A meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2017 |
Intravenous versus topical tranexamic acid in primary total hip replacement: A meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
Combined application versus topical and intravenous application of tranexamic acid following primary total hip arthroplasty: a meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Arthroplasty, Replacement, Hip; Blood Loss, Su | 2017 |
What influence do anticoagulants have on oral implant therapy? A systematic review.
Topics: Administration, Oral; Administration, Topical; Anticoagulants; Atrial Fibrillation; Contraindication | 2009 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Tranexamic acid in total knee replacement: a systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfu | 2011 |
Deep vein thrombosis, tranexamic acid, and a negative d-dimer.
Topics: Antifibrinolytic Agents; Antipsychotic Agents; Female; Fibrin Fibrinogen Degradation Products; Human | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2012 |
Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Controlled Cl | 2007 |
36 trials available for tranexamic acid and Deep Vein Thrombosis
| Article | Year |
|---|---|
Effect of Sequential Intravenous and Oral Tranexamic Acid on Hemoglobin Drop After Total Knee Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Repl | 2022 |
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Su | 2022 |
Medullary cavity application of tranexamic acid to reduce blood loss in tibial intramedullary nailing procedures-a randomized controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Exsanguination; Fracture Fixation, Intramedullary; Hu | 2023 |
Tranexamic acid is safe with respect to the risk of deep venous thrombosis in patients with hemophilic arthritis undergoing total knee arthroplasty without chemoprophylaxis: A prospective study.
Topics: Administration, Intravenous; Adult; Anticoagulants; Antifibrinolytic Agents; Arthritis; Arthroplasty | 2023 |
Comparison of oral vs. combined topical/intravenous/oral tranexamic acid in the prevention of blood loss in total knee arthroplasty: A randomised clinical trial.
Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Aged; Antifibrinolytic A | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Aged; Antifibrinolytic Agents; Case-Control Studies; Double-Blind Method; Fema | 2020 |
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Aged; Antifibrinolytic Agents; Case-Control Studies; Double-Blind Method; Fema | 2020 |
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Aged; Antifibrinolytic Agents; Case-Control Studies; Double-Blind Method; Fema | 2020 |
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Aged; Antifibrinolytic Agents; Case-Control Studies; Double-Blind Method; Fema | 2020 |
Combined use of intravenous and topical tranexamic acid efficiently reduces blood loss in patients aged over 60 operated with a 2-level lumbar fusion.
Topics: Administration, Topical; Age Factors; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2020 |
Tranexamic acid reduces blood cost in long-segment spinal fusion surgery: A randomized controlled study protocol.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; Human | 2020 |
Early intravenous tranexamic acid intervention reduces post-traumatic hidden blood loss in elderly patients with intertrochanteric fracture: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage | 2021 |
Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Blood Transfusion; Cesarean Section; Do | 2021 |
Intra-articular Application is More Effective Than Intravenous Application of Tranexamic Acid in Total Knee Arthroplasty: A Prospective Randomized Controlled Trial.
Topics: Administration, Intravenous; Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; | 2017 |
The effect of tranexamic acid on hidden bleeding in older intertrochanteric fracture patients treated with PFNA.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Fracture Fixation, Intramedullary; Hip | 2018 |
Multiple-Dose Intravenous Tranexamic Acid Further Reduces Hidden Blood Loss After Total Hip Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2018 |
OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Doubl | 2019 |
Tranexamic acid in primary total knee arthroplasty without tourniquet: a randomized, controlled trial of oral versus intravenous versus topical administration.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Arthritis, Rheumat | 2018 |
Comparative Efficacy of Intravenous With Intra-articular Versus Intravenous Only Administration of Tranexamic Acid to Reduce Blood Loss in Knee Arthroplasty.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2018 |
Intravenous and Oral Tranexamic Acid Are Equivalent at Reducing Blood Loss in Thoracolumbar Spinal Fusion: A Prospective Randomized Trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Blood Loss, Surgic | 2019 |
Clinical value of tranexamic acid in unilateral and simultaneous bilateral TKAs under a contemporary blood-saving protocol: a randomized controlled trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Clinical Protocol | 2014 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
The reduction in blood loss with intra-articular injection of tranexamic acid in unilateral total knee arthroplasty without operative drains: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Coagulation | 2015 |
[A PROSPECTIVE RANDOMIZED SELF-CONTROLLED STUDY ON EFFECT OF TRANEXAMIC ACID IN REDUCING BLOOD LOSS IN TOTAL KNEE ARTHROPLASTY].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2015 |
Combined Administration of Systemic and Topical Tranexamic Acid for Total Knee Arthroplasty: Can It Be a Better Regimen and Yet Safe? A Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2016 |
Single-dose tranexamic acid for reducing bleeding and transfusions in total hip arthroplasty: A double-blind, randomized controlled trial of different doses.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood | 2016 |
The Efficacy and Safety of Combination of Intravenous and Topical Tranexamic Acid in Revision Hip Arthroplasty: A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Administration, Topical; Aged; Animals; Antifibrinolytic Agents; Arthro | 2016 |
Multiple Boluses of Intravenous Tranexamic Acid to Reduce Hidden Blood Loss After Primary Total Knee Arthroplasty Without Tourniquet: A Randomized Clinical Trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomark | 2016 |
Tranexamic Acid Administration in Primary Total Hip Arthroplasty: A Randomized Controlled Trial of Intravenous Combined with Topical Versus Single-Dose Intravenous Administration.
Topics: Administration, Intravenous; Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Arthropl | 2016 |
Peri-articular tranexamic acid injection in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood T | 2016 |
Peri-articular tranexamic acid injection in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood T | 2016 |
Peri-articular tranexamic acid injection in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood T | 2016 |
Peri-articular tranexamic acid injection in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood T | 2016 |
The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2017 |
Efficacy of a Single Dose and an Additional Dose of Tranexamic Acid in Reduction of Blood Loss in Total Knee Arthroplasty.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2017 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2009 |
Effects of tranexamic acid on blood loss during total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgic | 2010 |
Risk of deep venous thrombosis in drain clamping with tranexamic acid and carbazochrome sodium sulfonate hydrate in total knee arthroplasty.
Topics: Adrenochrome; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Constriction; Female; | 2012 |
The comparative efficacies of intra-articular and IV tranexamic acid for reducing blood loss during total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Blood Loss, Sur | 2013 |
The postoperative blood-sparing efficacy of oral versus intravenous tranexamic acid after total knee replacement.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Su | 2004 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients.
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Double-Blind Method; Fema | 2006 |
38 other studies available for tranexamic acid and Deep Vein Thrombosis
| Article | Year |
|---|---|
No Difference in Blood Loss and Risk of Transfusion Between Patients Treated with One or Two Doses of Intravenous Tranexamic Acid After Simultaneous Bilateral TKA.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2022 |
[Effects of oral and intravenous tranexamic acid on perioperative blood loss after lumbar spinal canal decompression and fusion].
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Decompression; Humans; Postoperative Hemorrhage; Spin | 2022 |
Topical Tranexamic Acid Can Be Used Safely Even in High Risk Patients: Deep Vein Thrombosis Examination Using Routine Ultrasonography of 510 Patients.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Retrospective St | 2022 |
Does tranexamic acid increase venous thromboembolism risk among trauma patients? A prospective multicenter analysis across 17 level I trauma centers.
Topics: Adolescent; Adult; Humans; Prospective Studies; Pulmonary Embolism; Tranexamic Acid; Trauma Centers; | 2023 |
Postoperative ultrasound evaluation for deep vein thrombosis after knee replacement surgery performed with tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Humans | 2020 |
One Versus Two Doses of Intravenous Tranexamic Acid in Total Knee Arthroplasty.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2021 |
Periarticular Injection of Tranexamic Acid Reduces Blood Loss and the Necessity for Allogeneic Transfusion After Total Knee Arthroplasty Using Autologous Transfusion: A Retrospective Observational Study.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2018 |
Does tranexamic acid increase the risk of thromboembolism after bilateral simultaneous total knee arthroplasties in Asian Population?
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Asian Peop | 2018 |
Intravenous Tranexamic Acid Reduces Postoperative Blood Loss After High Tibial Osteotomy.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Humans; Infusions, Intravenous; Male; Mid | 2018 |
Intravenous Tranexamic Acid Reduces Postoperative Blood Loss After High Tibial Osteotomy.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Humans; Infusions, Intravenous; Male; Mid | 2018 |
Intravenous Tranexamic Acid Reduces Postoperative Blood Loss After High Tibial Osteotomy.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Humans; Infusions, Intravenous; Male; Mid | 2018 |
Intravenous Tranexamic Acid Reduces Postoperative Blood Loss After High Tibial Osteotomy.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Humans; Infusions, Intravenous; Male; Mid | 2018 |
Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Injury Severity Score | 2019 |
Comparison of three routes of administration of tranexamic acid in primary unilateral total knee arthroplasty: Analysis of a national database.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2019 |
Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis.
Topics: Aged; Blood Loss, Surgical; Carcinoma, Hepatocellular; Dabigatran; Humans; Infusions, Intravenous; L | 2019 |
Intravenous tranexamic acid safely and effectively reduces transfusion rates in revision total hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, | 2019 |
Intra-articular 1 g tranexamic acid administration during total knee arthroplasty is safe and effective for the reduction of blood loss and blood transfusion.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Blood Volume; Con | 2019 |
Can tranexamic acid and hydrogen peroxide reduce blood loss in cemented total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2014 |
Single perioperative dose of tranexamic acid in primary hip and knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplast | 2015 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2014 |
[Effectiveness of tranexamic acid in total knee arthroplasty].
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2014 |
Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis?
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Case-Control Studies; Female; Hip Joi | 2015 |
Does Tranexamic Acid Reduce Blood Loss and Transfusion Requirements Associated With the Periacetabular Osteotomy?
Topics: Acetabulum; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Dru | 2015 |
Intra-articular administration of tranexamic acid in total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Female; Humans; In | 2015 |
Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replace | 2016 |
Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty; Aspirin; Blood Loss, Surgical; Cohort Studies; Female; | 2016 |
A protocol for management of blood loss in surgical treatment of peritoneal malignancy by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Blood Component Transfusion; Blood Loss, Surgical; Cytoreduction Surgical Procedures; Factor VIII; F | 2016 |
Tranexamic acid in total joint arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty; Arthroplasty, Replacement; Blood Loss, Surgical; Humans; Post | 2016 |
Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.
Topics: Administration, Oral; Adult; Asian People; Dermatologic Agents; Facial Dermatoses; Female; Gastroint | 2016 |
Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.
Topics: Administration, Oral; Adult; Asian People; Dermatologic Agents; Facial Dermatoses; Female; Gastroint | 2016 |
Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.
Topics: Administration, Oral; Adult; Asian People; Dermatologic Agents; Facial Dermatoses; Female; Gastroint | 2016 |
Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.
Topics: Administration, Oral; Adult; Asian People; Dermatologic Agents; Facial Dermatoses; Female; Gastroint | 2016 |
Intravenous versus topical tranexamic acid administration in primary total knee arthroplasty: a meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2017 |
Chemical Thromboprophylaxis Is Not Necessary to Reduce Risk of Thromboembolism With Tranexamic Acid After Total Hip Arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Trans | 2017 |
Tranexamic acid use and risk of thrombosis in regular users ofantithrombotics undergoing primary total knee arthroplasty: a prospectivecohort study.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Fibrinolytic Agents; | 2018 |
A comparative, retrospective study of peri-articular and intra-articular injection of tranexamic acid for the management of postoperative blood loss after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Drainage; Female; | 2016 |
Prevalence of Venous Thromboembolic Events Is Low in Asians After Total Knee Arthroplasty Without Chemoprophylaxis.
Topics: Aged; Arthroplasty, Replacement, Knee; Asian People; Chemoprevention; Female; Humans; Male; Middle A | 2017 |
Low Risk of Thromboembolic Events After Routine Administration of Tranexamic Acid in Hip and Knee Arthroplasty.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anesthesia; Antifibrinolytic Agents; Arthropla | 2017 |
Tranexamic Acid Was Safe in Arthroplasty Patients With a History of Venous Thromboembolism: A Matched Outcome Study.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthropl | 2017 |
Hereditary haemorrhagic telangiectasia (HHT): negotiating between the Scylla of bleeding and Charybdis of thrombosis.
Topics: Adult; Antifibrinolytic Agents; Cardiomyopathy, Hypertrophic; Colectomy; Colostomy; Embolization, Th | 2008 |
Extensive venous thrombosis following administration of high-dose glucocorticosteroids and tranexamic acid in relapsed Evans syndrome.
Topics: Anemia, Hemolytic, Autoimmune; Dose-Response Relationship, Drug; Female; Glucocorticoids; Humans; Mi | 2008 |
Management of May-Hegglin anomaly referred for coronary artery bypass.
Topics: Adult; Anesthetics; Blood Platelets; Cell Size; Coronary Artery Bypass; Diabetes Complications; Diab | 2011 |
Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Drug Therapy, Combina | 2005 |
No increased risk of venous thrombosis in women taking tranexamic acid.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Case-Control Studies; Female; Humans; Middle Aged; Retro | 2001 |
No increased risk of venous thrombosis in women taking tranexamic acid.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Case-Control Studies; Female; Humans; Middle Aged; Retro | 2001 |
No increased risk of venous thrombosis in women taking tranexamic acid.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Case-Control Studies; Female; Humans; Middle Aged; Retro | 2001 |
No increased risk of venous thrombosis in women taking tranexamic acid.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Case-Control Studies; Female; Humans; Middle Aged; Retro | 2001 |
No increased risk of venous thrombosis in women taking tranexamic acid.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Case-Control Studies; Female; Humans; Middle Aged; Retro | 2001 |
No increased risk of venous thrombosis in women taking tranexamic acid.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Case-Control Studies; Female; Humans; Middle Aged; Retro | 2001 |
No increased risk of venous thrombosis in women taking tranexamic acid.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Case-Control Studies; Female; Humans; Middle Aged; Retro | 2001 |
No increased risk of venous thrombosis in women taking tranexamic acid.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Case-Control Studies; Female; Humans; Middle Aged; Retro | 2001 |
No increased risk of venous thrombosis in women taking tranexamic acid.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Case-Control Studies; Female; Humans; Middle Aged; Retro | 2001 |